Preventable risk factors for type 2 diabetes can be detected using noninvasive spontaneous electroretinogram signals

Ramsés Noguez Imm, Julio Muñoz-Benitez, Diego Medina, Everardo Barcenas, Guillermo Molero-Castillo, Pamela Reyes-Ortega, Jorge Armando Hughes-Cano, Leticia Medrano-Gracia, Manuel Miranda-Anaya, Gerardo Rojas-Piloni, Hugo Quiroz-Mercado, Luis Fernando Hernández-Zimbrón, Elisa Denisse Fajardo-Cruz, Ezequiel Ferreyra-Severo, Renata García-Franco, Juan Fernando Rubio Mijangos, Ellery López-Star, Marlon García-Roa, Lansingh Van Charles and Stéphanie C Thébault

PLOS ONE, 2023, vol. 18, issue 1, 1-26

Abstract: Given the ever-increasing prevalence of type 2 diabetes and obesity, the pressure on global healthcare is expected to be colossal, especially in terms of blindness. Electroretinogram (ERG) has long been perceived as a first-use technique for diagnosing eye diseases, and some studies suggested its use for preventable risk factors of type 2 diabetes and thereby diabetic retinopathy (DR). Here, we show that in a non-evoked mode, ERG signals contain spontaneous oscillations that predict disease cases in rodent models of obesity and in people with overweight, obesity, and metabolic syndrome but not yet diabetes, using one single random forest-based model. Classification performance was both internally and externally validated, and correlation analysis showed that the spontaneous oscillations of the non-evoked ERG are altered before oscillatory potentials, which are the current gold-standard for early DR. Principal component and discriminant analysis suggested that the slow frequency (0.4–0.7 Hz) components are the main discriminators for our predictive model. In addition, we established that the optimal conditions to record these informative signals, are 5-minute duration recordings under daylight conditions, using any ERG sensors, including ones working with portative, non-mydriatic devices. Our study provides an early warning system with promising applications for prevention, monitoring and even the development of new therapies against type 2 diabetes.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0278388 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 78388&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0278388

DOI: 10.1371/journal.pone.0278388

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().